Stent offers safe, effective, minimally invasive way to lower IOP in open-angle glaucoma patients
Dermot McGrath
Published: Wednesday, January 4, 2017
[caption id="attachment_7085" align="alignnone" width="242"]
Inga Kersten-Gomez MD[/caption]
The XEN Gel Stent (AqueSys) offers a safe, effective and minimally invasive way to lower intraocular pressure (IOP) in open-angle glaucoma (OAG) patients either as a standalone procedure or as an adjunct to phacoemulsification cataract surgery, according to a study presented at the XXXIV Congress of the ESCRS in Copenhagen, Denmark.
“The long-term efficacy shows good IOP reduction of the order of 39%, and a decrease of glaucoma medication use of around 56% after XEN Gel Stent implantation,” said Inga Kersten-Gomez MD.
The stent’s minimal invasiveness, strong safety profile and long-term efficacy make it a reasonable option as an additional method for surgical glaucoma therapy, sparing the conjunctiva and not blocking further filtration surgery, she added.
Dr Kersten-Gomez, of University Eye Hospital Bochum, Germany, said that the implant is the first ab-interno device which works by creating aqueous outflow from the anterior chamber into the non-dissected tissue of the subconjunctival space.
The procedure uses a collagen-derived, gelatin implant that is soft and flexible when hydrated, creating a soft, flexible drainage channel that conforms to the ocular tissue and cannot migrate or erode. Its gelatin material is biocompatible and is very well tolerated by the ocular tissues, she said.
A prospective, non-randomised, multicentre evaluation (Austria, Canada, Germany - see contributors below) included 66 eyes implanted with the XEN stent, 39 of which reached the four-year follow-up point. All patients had mild or moderate OAG, 51% were solo procedures, and 49% were combined with cataract surgery. Devices with two different inner lumen sizes of 140µm and 63µm were used in the study.
The best-medicated baseline IOP of 22.3mmHg decreased significantly to 13.5mmHg after four years, corresponding to a 39% reduction. The mean number of IOP-lowering medications also decreased significantly from 2.5 preoperatively to 1.1 postoperatively, a 56% reduction.
The visual field mean deviation showed no significant change over the course of the follow-up period. Eleven out of 66 patients (17%) were lost to follow-up and 16 patients (24%) had to be excluded from the final analysis because of secondary IOP-lowering procedures (one selective laser trabeculoplasty/SLT, 12 filtering surgeries, and three cyclodestructive procedures).
Dr Kersten-Gomez added that the results from her study were broadly in line with those reported in the three-year results of the international multicentre feasibility study, which enrolled 986 patients and which demonstrated effective IOP reduction of 32.7% at 12 months in 279 eyes, 33.1% at 24 months in 71 eyes, and 39.8% at 36 months in 33 eyes.
Inga Kersten-Gomez: inga.kersten-gomez@kk-bochum.de
CONTRIBUTORS TO THE MULTICENTRE STUDY
For Germany: I. Kersten-Gomez, L. Eisenkopf, H.B. Dick
For Austria: M. Lenzhofer (co-author), H. Reitsamer
For Canada: I. Ahmed
Inga Kersten-Gomez MD[/caption]
The XEN Gel Stent (AqueSys) offers a safe, effective and minimally invasive way to lower intraocular pressure (IOP) in open-angle glaucoma (OAG) patients either as a standalone procedure or as an adjunct to phacoemulsification cataract surgery, according to a study presented at the XXXIV Congress of the ESCRS in Copenhagen, Denmark.
“The long-term efficacy shows good IOP reduction of the order of 39%, and a decrease of glaucoma medication use of around 56% after XEN Gel Stent implantation,” said Inga Kersten-Gomez MD.
The stent’s minimal invasiveness, strong safety profile and long-term efficacy make it a reasonable option as an additional method for surgical glaucoma therapy, sparing the conjunctiva and not blocking further filtration surgery, she added.
Dr Kersten-Gomez, of University Eye Hospital Bochum, Germany, said that the implant is the first ab-interno device which works by creating aqueous outflow from the anterior chamber into the non-dissected tissue of the subconjunctival space.
The procedure uses a collagen-derived, gelatin implant that is soft and flexible when hydrated, creating a soft, flexible drainage channel that conforms to the ocular tissue and cannot migrate or erode. Its gelatin material is biocompatible and is very well tolerated by the ocular tissues, she said.
A prospective, non-randomised, multicentre evaluation (Austria, Canada, Germany - see contributors below) included 66 eyes implanted with the XEN stent, 39 of which reached the four-year follow-up point. All patients had mild or moderate OAG, 51% were solo procedures, and 49% were combined with cataract surgery. Devices with two different inner lumen sizes of 140µm and 63µm were used in the study.
The best-medicated baseline IOP of 22.3mmHg decreased significantly to 13.5mmHg after four years, corresponding to a 39% reduction. The mean number of IOP-lowering medications also decreased significantly from 2.5 preoperatively to 1.1 postoperatively, a 56% reduction.
The visual field mean deviation showed no significant change over the course of the follow-up period. Eleven out of 66 patients (17%) were lost to follow-up and 16 patients (24%) had to be excluded from the final analysis because of secondary IOP-lowering procedures (one selective laser trabeculoplasty/SLT, 12 filtering surgeries, and three cyclodestructive procedures).
Dr Kersten-Gomez added that the results from her study were broadly in line with those reported in the three-year results of the international multicentre feasibility study, which enrolled 986 patients and which demonstrated effective IOP reduction of 32.7% at 12 months in 279 eyes, 33.1% at 24 months in 71 eyes, and 39.8% at 36 months in 33 eyes.
Inga Kersten-Gomez: inga.kersten-gomez@kk-bochum.de
CONTRIBUTORS TO THE MULTICENTRE STUDY
For Germany: I. Kersten-Gomez, L. Eisenkopf, H.B. Dick
For Austria: M. Lenzhofer (co-author), H. Reitsamer
For Canada: I. Ahmed
Latest Articles
Beyond the Numbers
Empowering patient participation fosters continuous innovation in cataract surgery.
Thinking Beyond the Surgery Room
Practice management workshop focuses on financial operations and AI business applications.
Aid Cuts Threaten Global Eye Care Progress
USAID closure leads retreat in development assistance.
Supplement: ESCRS Clinical Trends Series: Presbyopia
Nutrition and the Eye: A Recipe for Success
A look at the evidence for tasty ways of lowering risks and improving ocular health.
New Award to Encourage Research into Sustainable Practices
Sharing a Vision for the Future
ESCRS leaders update Trieste conference on ESCRS initiatives.
Extending Depth of Satisfaction
The ESCRS Eye Journal Club discuss a new study reviewing the causes and management of dissatisfaction after implantation of an EDOF IOL.
Conventional Versus Laser-Assisted Cataract Surgery
Evidence favours conventional technique in most cases.
AI Scribing and Telephone Management
Automating note-taking and call centres could boost practice efficiency.